[A14-12] Canagliflozin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

Last updated 16.06.2014

Project no.:

Commission awarded on 14.03.2014 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Digestion, metabolism and hormones


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


Type 2 diabetes mellitus: Added benefit of canagliflozin is not proven

Drug manufacturer’s dossier did not provide suitable data for any therapeutic indication

Project no. Title Status
A14-24 Addendum to Commission A14-12 (canagliflozin) Commission completed

Federal Joint Committee (G-BA)

2014-09-04 A G-BA decision was published.

G-BA documents on this decision


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.